Julien Mamet, PhD
Chief Executive Officer & Co-Founder
Julien brings over 20 years of drug development experience and executive leadership in venture-backed biotechnology companies. A molecular biologist by training, he founded Adynxx and led the development of brivoligide, a novel therapeutic for postoperative pain, through Phase 1 and multiple Phase 2 clinical trials. His experience spans drug discovery, clinical development, intellectual property strategy, fundraising, and strategic transactions, including venture financings, licensing agreements, and a reverse merger. An inventor of Core Biotherapeutics’ technology platform, Julien is an author of peer-reviewed scientific publications and an inventor or co-inventor on seven patent families encompassing more than 80 filings worldwide.